- No public price. The homepage shows none.
- Not disclosed
- Not disclosed
- —
- —
- US
Radiology
CureMetrix
by CureMetrix · US
AI for mammograms: cmAngio quantifies breast arterial calcification (FDA-cleared), cmTriage prioritizes screening exams.
On this page
36/100Competitive
- Regulatory & Compliance18/28
FDA cleared (4 K-numbers on record)
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength16.6/26
3 peer-reviewed papers
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (4 K-numbers on record)
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers13/18
3 peer-reviewed papers
- RCT / meta-analysis / systematic review4/8
1 observational study (no RCT)
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
AI for mammograms: cmAngio quantifies breast arterial calcification (FDA-cleared), cmTriage prioritizes screening exams.
No public price. The homepage shows none.
Bottom line
CureMetrix sells FDA-cleared mammography software to breast imaging groups and hospital radiology departments. Its lead product is cmAngio, which detects and quantifies breast arterial calcification (BAC) on screening mammograms. The company also has cmTriage, cleared in 2019, while the products page lists cmAssist as cleared only in Brazil (ANVISA) and still in development in the US. A group that wants BAC scoring on Hologic or GE mammography has a cleared option here. A group that wants a US-cleared cancer CAD marker does not.
What is CureMetrix and who sells it?
CureMetrix, Inc. is a privately held company, described by Crunchbase and Tracxn as based in San Diego, California and founded in 2014. Crunchbase lists Blaise Barrelet, Homa Karimabadi, Kevin Harris and Navid Alipour as founders, and Tracxn names Alipour as CEO. The vendor site carries a 2026 copyright line for CureMetrix Inc.
Funding reports disagree. Dealroom shows a seed round from Analytics Ventures in August 2014, EvoNexus in May 2015 and a Series A in January 2017. Bold Brain Ventures announced an investment on November 26, 2018. PitchBook lists a $30 million Series C on September 17, 2024, while CB Insights shows only $250,000 raised in total.
What does it actually do?
The homepage describes cmAngio as AI-powered mammography analysis that "detects, quantifies, and contextualizes Breast Arterial Calcifications," with results in minutes. BAC is a vascular finding visible on a screening mammogram, so the pitch is that a breast imaging exam can also flag cardiovascular risk without another test.
The other listed products are cmTriage, cmAssist and cmDensity. A third-party summary describes cmTriage as scoring screening exams so high-suspicion cases are read first, and cmAssist as CAD that marks suspicious regions. The vendor lists cmDensity without a description.
The vendor claims an area under the curve (AUC) of 0.98 to 0.992 for cmAngio across digital breast tomosynthesis and full-field digital mammography cases. That is vendor data, not an independent measurement. It also claims the software is live at more than 400 sites in the US, based on internal data.
Which products are cleared by the FDA?
Four 510(k) records list the applicant Curemetrix, all Class II:
- K183285, cmTriage, decided March 8, 2019.
- K232367, cmAngio V1.0, decided October 5, 2023.
- K250754, cmAngio V1.6, decided April 10, 2025. Applied Radiology reports that this one extended validation to GE platforms.
- K260980, cmAngio V2.0, decided July 30, 2026. The homepage cites this number.
ITN reported validation on Hologic systems first, then GE. No PMA is listed. The homepage says "First and Only FDA Cleared Solution that Quantifies and Contextualizes," which is the vendor's wording. DeepHealth received its own BAC clearance (K254131, decided May 21, 2026, product code QIH), so CureMetrix has a cleared BAC competitor.
For cmAssist, the vendor's products page says it is cleared only in Brazil (ANVISA) and in development in the US. No cmAssist 510(k) exists.
What does the evidence say?
Peer-reviewed evidence tied clearly to a CureMetrix product is thin. Two breast imaging papers sit near the company's earlier products: one in the Journal of Breast Imaging on multicenter, multivendor validation of an FDA-approved algorithm for mammography triage (PMID 38416951), and a 2023 Cureus paper on AI detection of invasive lobular carcinoma on digital mammography (PMID 37303390). Neither title names the vendor. A 2026 JACC Cardiovascular Imaging paper on an age-based BAC percentile nomogram (PMID 42033436) covers the same topic as cmAngio.
The homepage quotes a breast radiologist from Prisma Health in praise, a quote the vendor chose.
What does it cost, and how does it connect?
Cost comes by quote only, and the homepage shows nothing.
Integration details are sparse. The homepage does not list PACS or EHR connections. EnvoyAI lists CureMetrix as a partner. HIPAA, SOC 2 and HITRUST status is not published.
Who is it for?
A breast imaging group with Hologic or GE equipment that wants BAC quantification added to its screening workflow is the natural buyer. A group that mainly wants cancer CAD cleared in the US should look at other vendors, since cmAssist has no US clearance.
The verdict
CureMetrix is a cleared-device vendor with a credible BAC product and a clearance record that runs from March 2019 to July 2026. Its weak spots are that the AUC and the site count come from the vendor alone, the funding reports contradict each other, and its CAD product has no US clearance. For BAC scoring on Hologic or GE equipment it belongs on the shortlist next to DeepHealth. For cancer CAD in the US it does not belong there at all.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | — | — | No public price. The homepage shows none. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries FDA 510(k) (multiple) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
What the literature says
3 peer-reviewed studies indexed on PubMed evaluate CureMetrix in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- A Novel Breast Arterial Calcification Age-Based Percentile Nomogram for the Incremental Prediction of Incidental Cardiovascular Events.
- Nerlekar N, Soh CH, Vasanthakumar S, et al.· JACC Cardiovasc Imaging· 2026
- Breast arterial calcification (BAC) detected on routine mammography is an emerging marker of cardiovascular risk in women. However, substantial age-related variability limits its clinical interpretability. Age-adjusted nomograms may improve risk stratification and communication. This study aims to determine whether age-adjusted BAC percentiles derived from mammography predict major adverse cardiovascular events (MACE) independent of atherosclerotic cardiovascular disease (ASCVD) risk scores. In this multicenter retrospective cohort study, 21,514 women without known cardiovascular disease and…
- Evaluation of an Artificial Intelligence System for Detection of Invasive Lobular Carcinoma on Digital Mammography.
- Arce S, Vijay A, Yim E, et al.· Cureus· 2023
- Introduction Early breast cancer detection with screening mammography has been shown to reduce mortality and improve breast cancer survival. This study aims to evaluate the ability of an artificial intelligence computer-aided detection (AI CAD) system to detect biopsy-proven invasive lobular carcinoma (ILC) on digital mammography. Methods This retrospective study reviewed mammograms of patients who were diagnosed with biopsy-proved ILC between January 1, 2017, and January 1, 2022. All mammograms were analyzed using cmAssist(CureMetrix, San Diego, California, United States), which is an AI CAD…
- Multicenter, Multivendor Validation of an FDA-approved Algorithm for Mammography Triage.
- Retson TA, Watanabe AT, Vu H, et al.· J Breast Imaging· 2022
- Artificial intelligence (AI)-based triage algorithms may improve cancer detection and expedite radiologist workflow. To this end, the performance of a commercial AI-based triage algorithm on screening mammograms was evaluated across breast densities and lesion types. This retrospective, IRB-exempt, multicenter, multivendor study examined 1255 screening 4-view mammograms (400 positive and 855 negative studies). Images were anonymized by providing institutions and analyzed by a commercially available AI algorithm (cmTriage, CureMetrix, La Jolla, CA) that performed retrospective triage at the st…
Other radiology
See the full radiology ranking
Siemens Healthineers AI-Rad Companion
by Siemens Healthineers
AI-Rad Companion: Chest CT, Chest X-ray, Brain MR, Prostate MR and Organs RT (radiotherapy contouring) modules, delivered through teamplay.
No public price on the vendor page.|FDA 510(k) (multiple) / CE Mark (MDD/MDR. MDR status not verified)
GE HealthCare AI Suite
by GE HealthCare
Portfolio of separately cleared AI-enabled GE HealthCare devices and software, including AIR Recon DL, Sonic DL, Critical Care Suite, Caption AI and icobrain.
No public price. Products are sold with scanners or as scanner options, on enterprise quotes.|FDA 510(k) (multiple)
Aidoc
by Aidoc
Clinical AI platform (aiOS) with FDA-cleared triage, notification and quantification algorithms for radiology and neurovascular care.
Private offer only. No trial is stated.|FDA 510(k) (multiple) / EU MDR 2017/745
Viz.ai
by Viz.ai
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
No public price. Sold to health systems after a demo request.|FDA 510(k) (multiple) / FDA De Novo (ContaCT, Viz HCM)